University at Buffalo - The State University of New York
Skip to Content
UBMD Physicians' Group

Clinical Trials

A Phase 3b, Multi-center, Open-label, Trial to Evaluate the Long Term Safety of Titrated Immediate -release Tolvaptan (OPC 41061,30mg to 120mg/day, Split-dose) in Subjects with Autosomal Dominant Polycystic Kidney Disease

Investigator

Rocco C. Venuto, MD Principal Investigator

Contact Information